Clinical characteristics of relapsed bladder cancer patients after curative CRT
| Variables | Total (n=48) | ||
| <12 months (n=16) | ≧12 months (n=32) | P value | |
| Gender (%) | |||
| Male | 14 (87.5) | 27 (84.4) | 0.77 |
| Female | 2 (12.5) | 5 (15.6) | |
| Age (median (IQR)) | 72(63-75) | 70(61-78) | 0.75 |
| ECOG-PS at pembrolizumab (%) | |||
| 0–1 | 13 (81.2) | 28 (12.5) | 0.57 |
| >2 | 3 (18.8) | 4 (87.5) | |
| Smoking history (%) | |||
| Never | 6 (37.5) | 11 (34.4) | 0.83 |
| Former/current | 10 (62.5) | 21 (65.6) | |
| Body mass index (%) | |||
| ≥25 | 3 (18.8) | 5 (15.6) | 0.79 |
| <25 | 13 (81.2) | 27 (84.4) | |
| Pelvic lymph node metastasis at curative therapy (%) | |||
| Yes | 7 (43.8) | 9 (28.1) | 0.28 |
| No | 9 (56.2) | 23 (71.9) | |
| Liver metastasis at pembrolizumab therapy (%) | |||
| Yes | 2 (12.5) | 5 (15.6) | 0.77 |
| No | 14 (87.5) | 27 (84.4) | |
| Visceral metastasis at pembrolizumab therapy (%) | |||
| Yes | 10 (62.5) | 25 (78.1) | 0.26 |
| No | 6 (37.5) | 7 (21.9) | |
| Hemoglobin concentration at first pembrolizumab therapy (%) | |||
| >100 g/L | 8 (50.0) | 14 (43.8) | 0.68 |
| ≤100 g/L | 8 (50.0) | 18 (56.2) | |
| NLR at first pembrolizumab therapy (%) (median (IQR)) | 5.50 (4.24–12.1) | 4.31 (2.72–7.47) | 0.14 |
ECOG-PS, Eastern Cooperative Oncology Group Performance Status; NLR, neutrophil-to-lymphocyte ratio.